Articles

Poll

Podcasts

Slideshows

Videos

WVE-006 drove production of M-AAT, which is protective of lung function, and reduced mutant Z-AAT, a cause of liver disease.

RestorAATion-2: WVE-006 Achieves Durable Serum AAT Protein Production in AATD

Check out expert perspectives on semaglutide’s FDA approval for MASH and new research on PBC, infectious disease screening, and more in this August 2025 recap.

6 Hepatology Headlines You Missed in August 2025

Any alcohol intake was linked to a greater risk of liver mortality, but healthy diet and physical activity lowered this risk across all drinking patterns.

Healthy Diet, Physical Activity Improve Alcohol-Related Liver Health

People with PBC and pruritus had a greater negative impact on HRQoL and reduced activity compared to those without pruritus, infrequently using medication.

Pruritus Increases HRQoL Burden in PBC, Underscoring Need for Effective Treatments

The cross-sectional analysis of NHANES data highlights obesity and overweight’s influence on the development of obesity-related conditions in US youth.

Rising Obesity Rates in Adolescents, Young Adults Tied to Major Health Complications

This episode highlights the groundbreaking approval of semaglutide for metabolic dysfunction-associated steatohepatitis, as well as GoodRx’s new Ozempic pricing.

Diabetes Dialogue: FDA Approves Semaglutide (Wegovy) for MASH

Hosts Nancy Reau and Kimberly Brown are joined by Mary Rinella to discuss the evolving MASH treatment landscape with GLP-1s and FGF21s in development.

Liver Lineup: GLP-1 RAs and FGF21s for MASH, with Mary Rinella, MD

The accelerated approval is based on findings from Part 1 of the ESSENCE trial and indicates the agent for noncirrhotic MASH with moderate to advanced fibrosis.

FDA Approves Semaglutide (Wegovy) Injection 2.4 mg for Noncirrhotic MASH 

Cholesterol in liver fat droplets has been found as a key driver of liver inflammation and fibrosis.

Study Reveals Cholesterol’s Role in Fibrotic Progression of Metabolic Liver Disease

Co-locating ID screening in an inpatient SUD program resulted in timely identification of and linkage to care for viral hepatitis and latent tuberculosis.

Infectious Disease Screening in Substance Use Treatment Programs Effective, Study Finds

Alpha-1 antitrypsin deficiency

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.